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The Barcelona Clinic Liver Cancer (BCLC) advanced stage (BCLC C) of hepatocellular carcinoma (HCC) includes a
heterogeneous population, where sorafenib alone is the recommended treatment. In this study, our aim was to assess treat-
ment and overall survival (OS) of BCLC C patients subclassified according to clinical features (performance status [PS],
macrovascular invasion [MVI], extrahepatic spread [EHS] or MVI 1 EHS) determining their allocation to this stage.
From the Italian Liver Cancer database, we analyzed 835 consecutive BCLC C patients diagnosed between 2008 and
2014. Patients were subclassified as: PS1 alone (n 5 385; 46.1%), PS2 alone (n 5 146; 17.5%), MVI (n 5 224; 26.8%),
EHS (n 5 51; 6.1%), and MVI 1 EHS (n 5 29; 3.5%). MVI, EHS, and MVI 1 EHS patients had larger and multifo-
cal/massive HCCs and higher alpha-fetoprotein (AFP) levels than PS1 and PS2 patients. Median OS significantly
declined from PS1 (38.6 months) to PS2 (22.3 months), EHS (11.2 months), MVI (8.2 months), and MVI 1 EHS (3.1
months; P < 0.001). Among MVI patients, OS was longer in those with peripheral than with central (portal trunk) MVI
(11.2 vs. 7.1 months; P 5 0.005). The most frequent treatments were: curative approaches in PS1 (39.7%), supportive
therapy in PS2 (41.8%), sorafenib in MVI (39.3%) and EHS (37.3%), and best supportive care in MVI 1 EHS patients
(51.7%). Independent prognostic factors were: Model for End-stage Liver Disease score, Child-Pugh class, ascites, platelet
count, albumin, tumor size, MVI, EHS, AFP levels, and treatment type. Conclusion: BCLC C stage does not identify
patients homogeneous enough to be allocated to a single stage. PS1 alone is not sufficient to include a patient into this
stage. The remaining patients should be subclassified according to PS and tumor features, and new patient-tailored thera-
peutic indications are needed. (HEPATOLOGY 2018;00:000-000).
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Hepatocellular carcinoma (HCC) represents aleading cause of mortality in patients withliver cirrhosis (LC).(1) Although all the
hepatology and oncology scientific societies recom-
mend surveillance for HCC with ultrasound—with or
without alpha-fetoprotein (AFP) determination—in
patients at risk,(2-4) only a minority of HCCs are
detected during surveillance in the Western world, and
Abbreviations: AFP, alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer; BSC, best supportive care; CEUS, contrast enhanced ultrasound; CI,
confidence interval; c-MVI, central MVI; CT, dynamic computed tomography; ECOG, Eastern Cooperative Oncology Group; EHS, extrahepatic spread;
HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; INR, international normalized ratio; ITA.LI.CA, Italian Liver
Cancer; MELD, Model for End-Stage Liver Disease; MRI, magnetic resonance imaging; MVI, macrovascular invasion; OLT, orthotopic liver trans-
plant; OS, overall survival; p-MVI, peripheral MVI; PS, performance status; TACE/TAE, transcatheter arterial chemoembolization/embolization; 90Y,
Yttrium90.
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therefore most tumors are not eligible for curative
treatments.(5-8) In fact, in countries without nation-
wide HCC surveillance programs, up to 30%-35% of
patients present with macrovascular invasion (MVI)
and/or extrahepatic spread (EHS) or with a poor per-
formance status (PS) caused by the development of the
tumor.(9-11) According to the Barcelona Clinic Liver
Cancer (BCLC) system, these patients are classified as
having “advanced” HCC (BCLC C), and the only rec-
ommended antitumoral treatment is systemic therapy
with the multikinase inhibitor, sorafenib.(3,12,13) In
fact, sorafenib proved to be able to significantly pro-
long the survival of BCLC C patients compared to
placebo in two randomized phase 3 trials, and its effi-
cacy has been confirmed in postmarketing studies.(13-
16) Post-hoc analyses of registration trials have con-
firmed the efficacy of this treatment in various patient
subclasses, including those with MVI and/or EHS, or
poor PS, although these features adversely affect sur-
vival.(15,17) Moreover, the occurrence of MVI or EHS
on treatment entails the poorest prognostic meaning,
indicating that the modality of cancer progression can-
not be disregarded when planning trials aimed at eval-
uating the efficacy of postsorafenib therapies.(18,19)
In order to evaluate whether, and how much, the clini-
cal and oncological features characterizing BCLC C stage
can influence the prognosis and treatment choice in clini-
cal practice, we assessed the management and survival of
these patients according to a subclassification based on
PS and presence of MVI and/or EHS. Our results pro-
vide propedeutic information to a patient-tailored man-
agement of advanced-stage HCC, likewise already
suggested for the intermediate (BCLC B) stage.(20,21)
Patients and Methods
PATIENTS
Data were extracted from the last version of the Ital-
ian Liver Cancer (ITA.LI.CA) database, including
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6,477 HCC patients consecutively evaluated and man-
aged from January 1987 to December 2014 at 24 Ital-
ian medical centers. Data were prospectively collected
and updated every 2 years. Before statistical evaluation,
the consistency and accuracy of the data set were
checked by the group coordinator (F.T.), and, when-
ever clarification or additional information were
needed, resubmitted to the generating center.
For the purpose of this study, we selected 835
patients diagnosed with a na€ıve advanced-stage HCC
(BCLC C), recruited by ITA.LI.CA centers from Jan-
uary 1, 2008 (first year of sorafenib reimbursement by
the Italian National Health Service) to December 31,
2014 (date of the last database update; Fig. 1). Patients
were subclassified in five groups according to the char-
acteristics that allocate a subject to the BCLC
advanced stage, that is, either PS1 or 2, or MVI, or
EHS, or both of these pathological characteristics.
Therefore, patients with PS0 were included into the
MVI, EHS, or MVI 1 EHS subgroups. The five sub-
groups thus identified are reported on in Table 1. PS
was assessed according to the Eastern Cooperative
Oncology Group (ECOG).(22)
DIAGNOSIS
HCC diagnosis was histological in 111 (13.3%)
cases whereas in the remaining cases it was based on
typical features in one or more imaging techniques
(dynamic computed tomography [CT], magnetic reso-
nance imaging [MRI], or contrast enhanced
ultrasound [CEUS]), according to the international or
Italian guideline editions available at the time of
patient recruitment.(3,23,24)
TREATMENT
Patients who underwent more than one treatment
were categorized according to the following hierarchy:
orthotopic liver transplant (OLT), hepatic resection,
ablation, radioembolization with Yttrium90 (90Y),
transcatheter arterial chemoembolization/embolization
(TACE/TAE), sorafenib, other treatments, and best
supportive care (BSC).
STATISTICAL ANALYSIS
Continuous data are shown as median and 95% con-
fidence interval (CI) and discrete variables as absolute
and relative frequencies. Child-Pugh score(25) was cat-
egorized as A, B 7 (threshold for eligibility to TACE),
and B 8-9, and the size of HCC (largest lesion of mul-
tinodular tumours) was categorized as 2, 2.1-5.0, and
TABLE 1. BCLC C Subgroups Classified According to the
Characteristics That Allocate Patients to the Advanced Stage
Patients
Subgroups Characteristics
PS1 Patients with PS1 alone (without MVI or EHS)
PS2 Patients with PS2 alone (without MVI or EHS)
MVI Patients with MVI and without EHS, regardless of PS
EHS Patients with EHS and without MVI, regardless of PS
MVI 1 EHS Patients with both MVI and EHS, regardless of PS
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FIG. 1. Flow chart of the patient
enrollment from the ITA.LI.CA
database.
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>5 cm. In Cox regression models, continuous variables
were categorized according to the median values or the
biochemical limit of normal range. Selected cutoffs
were: age 70 years, creatinine 1.2 mg/dL, albumin 3.5
g/dL, bilirubin 1.1 mg/dL, and international normal-
ized ratio (INR) 1.25. Platelet count was categorized
as <1003 109/L (cutoff for clinically significant portal
hypertension), 100-149 3 109/L, and 150 3 109/L
(lower normal value) and AFP as 20, 21-200, and
>200 ng/mL. Comparison of continuous data was car-
ried out using the Kruskal-Wallis test, and comparison
between discrete variables was carried out using the
Fisher’s exact test or the v2 test with Yates’ correction,
as appropriate.
Patient survival was calculated from the date of
HCC diagnosis to that of death or the last contact.
Overall survival (OS) was estimated by the Kaplan-
Meier method, and differences were tested with the
log-rank test. Variables associated (P < 0.10) with sur-
vival at univariate analysis were entered into a Cox’s
multivariate regression analysis. A P value <0.05 in a
two-tailed test was considered statistically significant.
Statistical analysis was performed using SPSS software
(v23.0; Apache Software Foundation, Chicago, IL).
ETHICS
The ITA.LI.CA database management conforms to
the current Italian legislation on patient confidentiality,
and this study conforms to the ethics guidelines of the
Declaration of Helsinki. All patients provided
informed consent to having their data recorded in an
anonymous way in the ITA.LI.CA database. The crea-
tion of the ITA.LI.CA database and its use for cooper-
ative studies were approved by the ethic committees/
institutional boards of participating centers.
Results
PATIENT CHARACTERISTICS
Table 2 reports demographic and clinical features of
BCLC C patient subclassified according to PS, and
presence of MVI and/or EHS. PS1 patients accounted
for 46.1% of the entire cohort (n 5 385), MVI
patients for 26.8% (n 5 224), PS2 patients for 17.5%
(n 5 146), EHS patients for 6.1% (n 5 51), and
MVI1EHS patients for 3.5% (n 5 29). Male sex was
more represented in all subclasses, but it was signifi-
cantly (P 5 0.001) more prevalent among MVI1EHS
patients (89.7%) as compared to other subclasses (PS1,
69.9%; PS2, 68.7%; MVI, 81.3%; EHS, 84.3%).
Child-Pugh class A was more frequent in EHS
patients (72.5%), followed by PS1 (61%), MVI
(53.1%), MVI 1 EHS (48.3%), and PS2 (41.8%)
patients (P 5 0.001). Ascites was more prevalent in
MVI 1 EHS patients (44.8%), followed by PS2
(40.4%), MVI (40.1%), PS1 (22.7%), and EHS
(22.9%) patients (P < 0.001). Moreover, HCC charac-
teristics and AFP levels were significantly different
among the various subclasses (P < 0.001). In particu-
lar, PS1 and PS2 patients presented more frequently
with smaller, single HCCs, and low AFP values,
whereas MVI 1 EHS patients had more frequently an
infiltrative/massive tumor and the highest AFP levels
(P < 0.001). Interestingly, median platelet count pro-
gressively increased from PS1 and PS2 patients to
MVI and EHS patients, with the highest values
observed in MVI 1 EHS patients (P < 0.001).
TREATMENT
Treatment distribution significantly differed among
BCLC C subclasses (Table 3). In PS1 patients, cura-
tive therapies (OLT 2.6%, resection 7.5%, and percu-
taneous ablation 29.6%) were more frequently applied
(39.7%), followed by transarterial treatments (35.3%)
and BSC (18.4%), whereas sorafenib was administered
only in 3.6% of patients. In PS2 patients, BSC was the
most frequent therapeutic approach (41.8%), followed
by curative (29.5%; mainly percutaneous ablation 24%)
and transarterial (17.1%) therapies, whereas sorafenib
was administered in 8.2% of these patients. Expect-
edly, in both MVI and EHS patients, sorafenib was
the most frequent treatment option (39.3% and 37.3%,
respectively), whereas the majority (51.7%) of patients
with MVI 1 EHS were managed with BSC.
In a further subanalysis that included Child-Pugh
class A patients only (Supporting Fig. S1), sorafenib
was the most common treatment not only in patients
with either MVI (47.1%) or EHS (45.9%), but also in
those with MVI 1 EHS (57.1%).
SURVIVAL ANALYSES
During a median follow-up of 13.1 months (95%
CI, 1.0-58.0), 462 (55.3%) patients died. The death
rate progressively increased across subclasses, as fol-
lows: 177 (46.0%) in the PS1 group, 78 (53.4%) in the
PS2 group, 149 (66.5%) in the MVI group, 37
(72.5%) in the EHS group, and 21 (72.4%) in the
MVI 1 EHS group. Causes of death were: cancer
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progression in 242 patients (52.4%), hepatic failure in
105 (22.7%), gastrointestinal hemorrhage in 14
(3.0%), renal failure in 6 (1.3%), infection in 6
(1.3%), embolism in 3 (0.6%), other causes (cardio-
vascular diseases, cerebral hemorrhage, and other can-
cers) in 42 (9.1%), and unknown causes in 44 patients
(9.5%).
In the whole population, median OS was 22.3
months (95% CI, 19.6-25.0). Survival remarkably dif-
fered across BCLC C subclasses (P < 0.001; Fig. 2A).
In particular, it was 38.6 months (95% CI, 32.5-44.6)
in PS1 patients, 22.3 months (95% CI, 14.4-30.3) in
PS2 patients, 11.2 months (95% CI, 9.8-12.5) in EHS
patients, 8.1 months (95% CI, 6.9-9.3) in MVI
TABLE 2. Demographic and Clinical Characteristics of the 835 Patients With Advanced (BCLC C) HCC
PS1 PS2 MVI EHS MVI 1 EHS
(n 5 385, 46.1) (n 5 146, 17.5) (n 5 224, 26.8) (n 5 51, 6.1) (n 5 29, 3.5) P Value
Age Years 72.0 (49.0-84.7) 73 (51.0-85.6) 67 (46.0-82.8) 69 (50.0-83.0) 68 (62-73) <0.001
Sex Male 269 (69.9) 100 (68.5) 182 (81.2) 43 (84.3) 26 (89.7) 0.001
Etiology HCV 190 (49.4) 70 (47.9) 94 (42.0) 17 (33.3) 10 (34.5) 0.112
HBV (6 HDV) 20 (5.2) 12 (8.2) 28 (12.5) 5 (9.8) 2 (6.9)
Alcohol 66 (17.1) 20 (13.7) 33 (14.7) 10 (19.6) 5 (17.2)
NAFLD/
cryptogenic
38 (9.9) 10 (6.8) 22 (9.8) 4 (7.8) 5 (17.2)
Multietiology 51 (13.2) 22 (15.1) 41 (18.3) 12 (23.5) 7 (24.1)
Other 11 (2.9) 5 (3.4) 3 (1.3) 1 (2.0) 0 (0.0)
Unknown 9 (2.3) 7 (4.8) 3 (1.3) 2 (3.9) 0 (0.0)
ECOG-PS 0 — — 98 (43.8) 22 (43.1) 10 (34.5) <0.001
1 385 (100) — 83 (37.1) 21 (41.2) 15 (51.7)
2 — 146 (100) 43 (19.2) 8 (15.7) 4 (13.8)
Albumin g/dL 3.5 (2.7-4.3) 3.3 (2.5-4.2) 3.4 (2.4-4.4) 3.5 (2.5-4.4) 3.5 (2.9-4.2) 0.014
Bilirubin mg/dL 1.2 (0.5-3.6) 1.2 (0.4-3.7) 1.2 (0.5-4.8) 1 (0.4-6.7) 1.5 (0.7-11.8) 0.149
Creatinine mg/dL 0.9 (0.5-1.5) 1 (0.5-2.3) 0.8 (0.5-1.5) 0.8 (0.5-3.0) 0.9 (0.5-5.5) 0.004
INR 1.2 (0.9-1.7) 1.2 (1.0-1.7) 1.2 (1.0-1.6) 1.1 (0.9-1.5) 1.2 (1.0-1.6) 0.101
Platelet count 109/L 105 (44-261) 102 (44-305) 136 (50-358) 165 (63-444) 173 (52-404) <0.001
Child-Pugh score 5-6 235 (61.0) 61 (41.8) 119 (53.1) 37 (72.5) 14 (48.3) 0.001
7 73 (19.0) 35 (24.0) 46 (20.5) 5 (9.8) 8 (27.6)
8-9 77 (20.0) 50 (34.2) 59 (26.3) 9 (17.6) 7 (24.1)
MELD Score 10 (6-18) 10 (6-20) 10 (6-16) 9 (6-18) 10 (6-20) 0.111
Esophageal varices Present 206 (60.4) 79 (65.8) 107 (59.1) 18 (43.9) 17 (65.4) 0.163
HCC gross pathology Single 202 (53.6) 72 (51.1) 48 (22.1) 7 (14.3) 2 (6.9) <0.001
Multifocal 159 (42.2) 55 (39.0) 87 (40.1) 30 (61.2) 10 (34.5)
Infiltrating/
massive
16 (4.2) 14 (9.9) 82 (37.8) 12 (24.5) 17 (58.6)
HCC main nodule size 2 cm 101 (28.4) 29 (21.6) 13 (7.1) 2 (4.5) 1 (4.0) <0.001
>2  5 cm 188 (52.8) 71 (53.0) 69 (37.7) 13 (29.5) 7 (28.0)
5 cm 67 (18.8) 34 (25.4) 101 (55.2) 29 (65.9) 17 (68.0)
AFP ng/mL 12.7 (2.0-2,309.0) 15.0 (2.0-635) 264 (3.4-57,140) 108.5 (2.5-24,997) 661 (2.4-61,400) <0.001
Data are shown as median and 95% CI or absolute value and (percentage).
Abbreviations: CLC, Barcelona Clinic Liver Cancer; HDV, hepatitis D virus; NAFLD, nonalcoholic fatty liver disease.
TABLE 3. Treatment Distribution in the Various BCLC C Subclasses
PS1
n 5 385 (46.1)
PS2
n 5 146 (17.5)
MVI
n 5 224 (26.8)
EHS
n 5 51 (6.1)
MVI 1 EHS
n 5 29 (3.5)
Liver transplant 10 (2.6) 1 (0.7) — — —
Resection 29 (7.5) 7 (4.8) 23 (10.3) 2 (3.9) 1 (3.4)
Ablation 114 (29.6) 35 (24.0) 4 (1.8) 1 (2.0) —
TA(C)E 133 (34.5) 25 (17.1) 11 (4.9) 7 (13.7) —
TARE 3 (0.8) — 10 (4.5) 2 (3.9) —
Sorafenib 14 (3.6) 12 (8.2) 88 (39.3) 19 (37.3) 12 (41.4)
Other 11 (2.8) 5 (3.5) 16 (7.1) 5 (9.8) 1 (3.4)
BSC 71 (18.4) 61 (41.8) 72 (32.1) 15 (29.4) 15 (51.7)
Data are shown as absolute value and (percentage).
Abbreviation: TARE, 90Y transarterial radioembolization.
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patients, and 3.1 months (95% CI, 2.1-4.0) in MVI 1
EHS patients. PS1 patients had a longer survival com-
pared to PS2 patients (P 5 0.001). MVI and EHS
patients had similar OS (P5 0.663), which was signif-
icantly shorter as compared to that of PS2 patients (P
< 0.001, for both MVI and EHS). Last, MVI 1
EHS patients had the shortest survival, which was sig-
nificantly different from that of both MVI (P < 0.001)
and EHS (P 5 0.001) patients.
In order to assess whether the degree of vascular
invasion had a prognostic impact, MVI patients were
further subdivided according to the location/extension
of vascular invasion, as follows: central MVI (c-MVI)
if it involved the main portal trunk (n 5 86; 38.4%)
and peripheral MVI (p-MVI) if only first-order or seg-
mental portal vein branches were involved (n 5 108;
48.2%). This substratification was possible in 86.6% of
MVI patients, because the location/extension of vascu-
lar invasion was missing in 30. Median OS was longer
in patients with p-MVI (11.2 months; 95% CI, 7.4-
15.0) as compared to those with c-MVI (6.1 months;
95% CI, 4.1-8.2; P 5 0.005; Fig. 2B).
Last, we performed a sensitive analysis to assess the
impact of Child-Pugh classes on the survival of the
BCLC C subgroups. Class A patients’ survival was sig-
nificantly longer in the subgroups of patients with a
PS1 alone and in those with a p-MVI, and a trend
toward significance was observed in the PS2 group
(Supporting Fig. S2).
PROGNOSTIC INDICATORS
The prognostic relevance of demographic, clinical,
biochemical, and tumoral parameters, as well as HCC
treatment, were tested in univariate analysis (Table 4).
This analysis showed that mortality was associated
with: male sex, hepatitis B virus (HBV) etiology, mul-
tietiology, PS2, presence of esophageal varices, ascites,
Child-Pugh class B, Model for End-stage Liver Dis-
ease (MELD) score >10, creatinine >1.2 mg/dL,
albumin <3.5 g/dL, INR >1.25, bilirubin >1.1 mg/
dL, platelet count 150 3 109/L, HCC gross pathol-
ogy, tumor size >5 cm, MVI, EHS, AFP >200 ng/
mL, and treatment. These variables were entered into
a multivariate analysis. In order to avoid collinearities,
three models were created (Table 5). All models
included the oncological features significantly associ-
ated with mortality whereas they differed in terms of
variables exploring liver function: Model 1 included
the Child-Pugh score; model 2 the MELD score; and
model 3 the variables forming these scores.
In all models, platelet count (cutoff 150 3 109/L),
MVI (both peripheral and central), EHS, AFP (cutoff
200 ng/mL), and type of treatment were
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FIG. 2. Survival of patients according to BCLC C subclasses (A) and according to the type of MVI extension (black line, p-MVI;
gray line, c-MVI (main portal trunk); B).
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independently associated with survival. Further inde-
pendent predictors of survival were:
- in model 1: Child-Pugh class
- in model 2: MELD score (10), nodule size (5
cm), ascites and albumin (3.5 g/dL)
- in model 3: ascites and albumin (3.5 g/dL).
OUTCOME OF PATIENTS
UNDERGOING BSC
In order to describe the “natural” history of these
patients, we also assessed the outcome of those who
received BSC alone. Even in this analysis, median
OS was significantly different among some sub-
classes (P < 0.001): PS1 and PS2 patients had simi-
lar survival (13.2 [95% CI, 7.9-18.5] vs. 11.2
months [95% CI, 8.0-14.3]; P 5 0.235) and signifi-
cantly longer (P  0.024) than that of MVI and
EHS patients (4.0 [95% CI, 2.2-5.9] and 5.1
months [95% CI 1.7-8.4], respectively). OS reached
the lowest figure in MVI 1 EHS patients (2.0
months [95% CI 1.9-2.1]; P  0.045, compared to
MVI and EHS patients; Fig. 3).
Discussion
European and American guidelines for HCC man-
agement have endorsed the BCLC staging system in
order to stratify patients and recommend the first-line
therapy for each stage.(3,23) However, in this system,
the advanced stage—like the intermediate stage—
encompasses a very heterogeneous patient population
given that the allocation to this stage may be driven by
the presence of any of the following features: PS1 or 2,
TABLE 4. Risk Factors for Mortality in Patients With
Advanced HCC (BCLC C Stage)
Univariate
P ValueHR (95% CI)
Age, years
70 1
>70 0.90 (0.75-1.08) 0.270
Sex
Female 1
Male 1.24 (1.00-1.53) 0.050
Etiology
HCV 1
HBV (6 HDV) 1.61 (1.15-2.23) 0.005
Alcohol 1.14 (0.87-1.49) 0.344
NAFLD/c ryptogenic 1.31 (0.95-1.82) 0.102
Multietiology 1.25 (0.96-1.82) 0.091
Other 1.39 (0.81-2.38) 0.238
Unknown 0.93 (0.50-1.70) 0.805
ECOG-PS
0-1 1
2 1.47 (1.20-1.80) <0.001
Child-Pugh class
A 1
B7 1.67 (1.32-2.12) <0.001
B8-9 2.18 (1.75-2.71) <0.001
MELD score
10 1
>10 1.48 (1.23-1.78) <0.001
Esophageal varices
No 1
Yes 1.21 (0.98-1.48) 0.076
Ascites
No 1
Yes 2.12 (1.74-2.58) <0.001
HCC gross pathology
Single 1
Multifocal 1.65 (1.34-2.04) <0.001
Infiltrating/massive 3.57 (2.77-4.61) <0.001
Macrovascular invasion
No 1
Peripheral 2.25 (1.73-2.93) <0.001
Central 4.31 (3.31-5.60) <0.001
HCC main nodule size, cm
2 1
2-5 1.19 (0.90-1.55) 0.216
>5 2.27 (1.71-3.00) <0.001
EHS
No 1
Yes 2.72 (2.05-3.59) <0.001
AFP, ng/mL
20 1
21-200 1.21 (0.94-1.55) 0.134
>200 2.16 (1.71-2.72) <0.001
Albumin, g/dL
3.5 1
<3.5 1.56 (1.29-1.88) <0.001
Bilirubin, mg/dL
1.1 1
>1.1 1.27 (1.06-1.53) 0.011
INR
<1.25 1
1.25 1.31 (1.08-1.59) 0.006
Creatinine, mg/dL
1.2 1
>1.2 1.28 (1.00-1.64) 0.054
TABLE 4. Continued
Univariate
P ValueHR (95% CI)
Platelets, 3109/L
<100 1
100-149 1.06 (0.83-1.34) 0.661
150 1.27 (1.01-1.58) 0.037
Treatment
Curative 1
TACE/TAE/TARE 1.89 (1.41-2.52) <0.001
Sorafenib 4.75 (3.52-6.39) <0.001
BSC 7.34 (5.55-9.70) <0.001
Other/unknown 2.21 (1.27-3.83) 0.005
Abbreviations: HDV, hepatitis D virus; HR, hazard ratio;
NAFLD, nonalcoholic fatty liver disease; TARE, 90Y transarte-
rial radioembolization.
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TABLE 5. Independent Risk Factors for Mortality in Patients With Advanced HCC (Multivariate Regression Analysis)
Multivariate
(Model 1)
P Value
Multivariate
(Model 2)
P Value
Multivariate
(Model 3)
P ValueHR (95% CI) HR (95% CI) HR (95% CI)
Sex
Female 1 1 1
Male 0.99 (0.73-1.36) 1.000 1.01 (0.74-1.38) 0.953 1.01 (0.73-1.39) 0.957
Etiology
HCV/alcohol/NAFLD/
cryptogenic/other/unknown
1 1 1
Multietiology 1.05 (0.74-1.47) 0.800 1.03 (0.73-1.46) 0.871 1.01 (0.71-1.43) 0.976
HBV (6 HDV) 1.40 (0.88-2.22) 0.152 1.15 (0.72-1.83) 0.563 1.18 (0.73-1.88) 0.501
ECOG-PS
0-1 1 1 1
2 1.18 (0.87-1.60) 0.290 1.21 (0.89-1.64) 0.218 1.22 (0.90-1.66) 0.203
Esophageal varices
No 1 1 1
Yes 1.19 (0.91-1.57) 0.210 0.97 (0.73-1.29) 0.824 0.97 (0.73-1.29) 0.850
Ascites
No 1 1
Yes 1.78 (1.32-2.41) <0.001 1.80 (1.33-2.43) <0.001
Child-Pugh class
A 1
B7 2.08 (1.51-2.86) <0.001
B8-9 2.90 (2.08-4.04) <0.001
MELD score
10 1
>10 1.50 (1.13-2.00) 0.005
Creatinine (mg/dL)
1.2 1 1
>1.2 1.00 (0.70-1.43) 0.986 1.03 (0.71-1.49) 0.874
Albumin (g/dL)
3.5 1 1
<3.5 1.37 (1.03-1.82) 0.029 1.40 (1.05-1.85) 0.021
Bilirubin (mg/dL)
1.1 1
>1.1 1.21 (0.90-1.62) 0.209
INR
1.25 1
>1.25 1.23 (0.92-1.64) 0.157
Platelets (3109/L)
<150 1 1 1
150 1.44 (1.08-1.91) 0.012 1.45 (1.10-1.92) 0.009 1.50 (1.12-2.00) 0.007
HCC gross pathology
Single 1 1 1
Multifocal 1.19 (0.88-1.61) 0.269 1.21 (0.89-1.64) 0.223 1.19 (0.87-1.61) 0.273
Infiltrating/massive 1.03 (0.64-1.64) 0.917 1.00 (0.62-1.60) 0.996 1.00 (0.63-1.61) 0.993
Main nodule size (cm)
5 1 1 1
>5 1.24 (0.91-1.67) 0.168 1.39 (1.02-1.90) 0.037 1.37 (1.00-1.87) 0.051
MVI
No 1 1 1
Peripheral 2.95 (1.84-4.72) <0.001 2.34 (1.43-3.83) 0.001 2.30 (1.40-3.77) 0.001
Central 2.59 (1.66-4.05) <0.001 2.80 (1.79-4.36) <0.001 2.75 (1.76-4.31) <0.001
EHS
No 1 1 1
Yes 2..46 (1.61-3.77) <0.001 2.22 (1.45-3.40) <0.001 2.23 (1.45-3.44) <0.001
AFP (ng/mL)
200 1 1 1
>200 1.44 (1.06-1.96) 0.020 1.52 (1.11-2.08) 0.010 1.49 (1.09-2.04) 0.013
Treatment
Curative 1 1 1
TACE/TAE/TARE 2.34 (1.59-3.44) <0.001 2.59 (1.73-3.86) <0.001 2.56 (1.72-3.81) <0.001
Sorafenib 1.59 (0.94-2.69) 0.083 2.43 (1.42-4.17) 0.001 2.42 (1.41-4.16) 0.001
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MVI, and EHS.(20,21) Moreover, liver function can
range from Child-Pugh A5 to B9 score. Nevertheless,
the suggested treatment for all these patients is sorafe-
nib, which has a suboptimal tolerability and a modest
efficacy, being able to prolong the median survival by
about 3 months compared to placebo.(13,14)
SURVIVAL DIFFERENCES
In a real-world setting, such as the one described in
our study, BCLC C patients showed a markedly dif-
ferent prognosis according to the characteristics that
determined the assignment to this stage. In particular,
when a mild impairment of general health status (PS1)
was the only reason for the allocation, approximately
75% of cases were treated with curative or transarterial
treatments, and sorafenib was seldom (3.6% of cases)
considered the best therapeutic option. In fact, the
presence of a PS1 (i.e., patients restricted in physically
strenuous activity, but ambulatory and able to carry out
a light/sedentary work(22)) does not preclude the access
to all available HCC treatments. We do not have data
on posttreatment morbidity in these patients, in partic-
ular in those who underwent treatment with curative
intent—and this represents a limitation of this analy-
sis—although approximately 1 of 5 PS1 patients were
fit enough to undergo a second-line treatment, and
this subclass had a median survival long enough (38.6
months) to compete with that of patients with an
intermediate stage tumor.(21) Furthermore, the attribu-
tion of a tumour-dependent—as recommended by the
BCLC system—mild deterioration of PS is very sub-
jective in the setting of HCC given that several con-
founding factors, such as advanced age (median age in
our series ranged from 67 to 73 years), presence of cir-
rhosis (Child-Pugh class B in 45% of our patients),
and the frequent presence of extrahepatic comorbid-
ities may play a major role. Further evidence of this
finding is provided by the distribution of the main var-
iables related to liver function (Child-Pugh class,
MELD score) and of indirect markers of portal
hypertension (platelet count) in patients with various
PS (Supporting Table S1), showing that a decrease in
liver function and signs of portal hypertension are asso-
ciated with worsening PS, although more than half of
patients with PS1 had fully compensated liver disease.
Last, this finding is also further emphasized by the
evaluation of HCC lines of treatment in the various
study subgroups (Supporting Table S2): This analysis
showed that patients with PS1 more frequently went
through more than one line of HCC treatment as
compared to the other groups, underscoring the fact
that these patients are able to tolerate more than one
treatment, and that this occurrence does not seem to
have a negative effect on survival. For these reasons,
the Italian community of hepatologists recommended
TABLE 5. Continued
Multivariate
(Model 1)
P Value
Multivariate
(Model 2)
P Value
Multivariate
(Model 3)
P ValueHR (95% CI) HR (95% CI) HR (95% CI)
BSC 6.09 (3.98-9.31) <0.001 7.06 (4.53-10.99) <0.001 7.32 (4.69-11.43) <0.001
Other/unknown 0.82 (0.31-2.21) 0.700 0.90 (0.33-2.42) 0.828 0.97 (0.36-2.63) 0.958
Bolded values are statistical significant values.
Abbreviations: HDV, hepatitis D virus; HR, hazard ratio; NAFLD, nonalcoholic fatty liver disease; TARE, 90Y transarterial
radioembolization.
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FIG. 3. Survival of patients treated with BSC in the BCLC C
subclasses.
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that PS1 per se should no longer be accepted as a char-
acteristic sufficient to assign patients to the advanced
stage.(24) Noteworthy, following this suggestion, 46%
of our BCLC C patients would be reclassified into ear-
lier HCC stages. Last, as far as this issue is concerned,
Hsu et al. showed that reassigning PS1 patients to
BCLC B improved the prognostic ability and gradient
monotonicity of BCLC classification.(26)
Interestingly, in PS2 patients, the most common
treatment was BSC (41.8%) likely because of a high
prevalence of ascites and of a Child-Pugh B 8-9 score,
given that both of these characteristics generally pre-
clude all active HCC treatments but OLT. Nonethe-
less, these patients also showed a rather long survival
(median, 22.3 months), which exceeded by far that of
patients with MVI and/or EHS. Such a result, con-
firmed in patients managed with BSC alone (Fig. 3),
would indicate that unfavorable oncological features
purport a worse prognosis as compared to a mild/mod-
erate deterioration of general conditions attributed to
cirrhosis and/or to extrahepatic comorbidities.
When either MVI or EHS were present, sorafenib
was the most frequently administered treatment
(approximately 40% of cases in both subclasses), partic-
ularly in Child-Pugh A patients (46% and 57%,
respectively) for whom, in Italy, the expense for this
therapy is charged to the National Health System.
However, it is worth noting that 10% of patients with
MVI underwent surgical resection. This treatment
option was likely suggested by studies showing that
hepatectomy provides a better outcome as compared to
nonsurgical treatments when portal invasion is limited
to peripheral branches.(27) Moreover, 4.5% of MVI
patients underwent 90Y radioembolization, which has
been reported to provide median survivals of 17-19
months in patients with peripheral MVI.(28,29)
Our study also showed that survival of EHS and p-
MVI patients was similar, but significantly (P 5
0.014) longer than in the c-MVI subgroup, suggesting
that the invasion of portal trunk represents the worst
oncological feature of the advanced HCC stage. This
finding seems at variance with the one reported in an
Eastern series, in which patients with EHS had a sur-
vival similar to that of subjects with a “significant”
(lobar, main trunk, or bilateral) MVI.(30) However, in
that study, a distinction between c-MVI and p-MVI
was not performed. Therefore, we feel that the extent
of MVI represents a key prognostic indicator for HCC
patients, and that the distinction between central and
peripheral portal invasion is clinically meaningful. Our
assumption is supported by a recent study reporting
that a segmental/sectorial invasion of portal branches is
associated with a more favorable outcome as compared
to left/right branches or main trunk invasion.(31)
Our study indicates that, even in the sorafenib era,
we should expect a very short survival (median, 3.1
months) in patients with both MVI and EHS attrib-
uted to the most advanced tumor burden and the fact
that more than 50% of them belong to Child-Pugh
class B (Table 1), limiting the applicability and efficacy
of sorafenib.
TREATMENT DIFFERENCES
The heterogeneity of BCLC C patients was also pri-
marily responsible for the frequent deviation from the
“one size fits all” approach recommended by the Euro-
pean and American guidelines for these cases.(3,23) In
fact, we found a frequent shift toward curative or trans-
arterial therapies in patients allocated to the advanced
stage attributed to PS1 or 2, suggesting that, in clinical
practice, oncological characteristics—rather than PS—
guide treatment selection. A certain shift toward
locoregional treatments was also observed in MVI
patients, and, unexpectedly, this deviation was also
observed in patients with EHS. The individual scru-
tiny of these cases (data not reported) showed that it
generally occurred in patients with metastatic lymphn-
odes at the hepatic hylum or with tiny (<1 cm) pulmo-
nary nodules, likely misclassified as benign at the time
of treatment. This shift and, above all, a compromised
liver function (Child-Pugh B class) restrained the use
of sorafenib in MVI and/or EHS patients.
Our results are not isolated, given that another
European study carried out in the sorafenib era
reported a poor adherence to Western guidelines in the
advanced HCC stage.(32) In that study, two thirds of
cases were treated at variance with the BCLC algo-
rithm. Besides the possible presence of a severely com-
promised liver function, a reason behind this frequent
deviation relies on the fact that the BCLC algorithm
does not propose any therapy, potentially more effec-
tive than sorafenib, in well-selected cases, particularly
in Child-Pugh class A and PS1 patients.(32,33) This
limitation cannot be (and is not) any longer accepted
for an updated management of HCC patients. As a
matter of fact, using a patient-tailored management
established by a multidisciplinary expert team, we
achieved a median survival of 22.3 months in BCLC
C patients, which is remarkably longer than the one
achieved with sorafenib in both randomized and post-
marketing Western studies.(14,15) To reconcile our
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results with those of the cited series, we can suppose
that the presence of a PS1 or 2 was not sufficient to
enroll patients in those studies. In fact, the reported
median survivals are closer to those of our MVI or
EHS patients, rather than to those of our PS1 or PS2
patients.
Last, we identified a number of independent predic-
tors of mortality for BCLC C patients—most of them
expected or well known—such as liver function tests
(Child-Pugh and MELD score), tumor features (AFP,
MVI, and EHS), and treatment. Considering Child-
Pugh classes, we found that a poor liver function sig-
nificantly affected prognosis only in patients with a
limited tumor burden (Supporting Fig. S2). Interest-
ingly, in the setting of advanced HCC, we confirmed
the dismal prognostic meaning of increasing platelet
count, which has been already described in unselected
HCC patients. This finding would support the
hypothesized participation of platelets in the HCC
microenvironment, with the ability to promote tumor
growth and drug resistance.(34)
LIMITATIONS
The retrospective nature of our study does not allow
us to exclude unintended biases and precluded a regi-
mented follow-up of patients and an estimation of the
effect of unrecorded confounding factors, such as
severity of comorbidities, local facility to access to cer-
tain treatments, and patient’s and physician’s preferen-
ces. However, these shortcomings should be weighed
in light of a multicenter large registry collecting real-
world observational data generated by the clinical prac-
tice and partnership of academic and nonacademic
centers. Moreover, our data pertain to an European
population of patients mainly infected with hepatitis C
virus (HCV), and a validation in other populations
with different clinical and ethnic background, and
where inherent variations may exist in the provision of
locoregional and systemic therapies are needed and
eagerly awaited.
Our results indicate that: (1) PS1 per se should not
be considered sufficient to allocate a patient to the
advanced BCLC stage, given that PS1 patients with
limited tumor burden are generally eligible to surgical
or locoregional therapies and display a long survival;
(2) in Italy, management of HCC escapes from a rigid
application of the BCLC algorithm-inspired guide-
lines, having embraced the principles of Precision
Medicine.(35) This method postulates a management
established by a multidisciplinary expert team and
principally based on an individualized (rather than
stage-based) approach in order to offer the best treat-
ment to each patient, according to his or her own
characteristics.(24)
Our study emphasises the urgent need of an articu-
late reclassification of HCC patients with MVI and/or
EHS, capable to refine our prognostic ability, and gen-
erate new therapeutic paradigms aimed at improving
outcomes for these patients.
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